MedTrace Logo

To Investigate the Role of Upstream High Dose Statin in STEMI

NCT01050348 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2018-10-05

No results posted yet for this study

Summary

This is a double-blinded randomized placebo controlled trial investigating the role of upstream 80mg Atorvastastin-calcium in patients undergoing percutaneous intervention for acute STEMI.

Conditions

  • Acute Myocardial Infarction

Interventions

DRUG

Atorvastatin calcium

Eligible patients will receive 80mgs of atorvastatin orally upon admission to hospital prior to percutaneous intervention of the affected artery. Dose of post-procedural statin will be at the discretion of the cardiologist.

DRUG

Inactive Placebo

Eligible patients will receive a placebo orally upon admission to hospital prior to percutaneous intervention of the affected artery.

Sponsors & Collaborators

  • West Penn Allegheny Health System

    collaborator OTHER

  • The Western Pennsylvania Hospital

    lead OTHER

Principal Investigators

  • Venkatraman Srinivasan, MD · West Penn Allegheny Health System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01050348 on ClinicalTrials.gov